Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director · CEO | August 16, 2024 | August 20, 2024 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | December 16, 2022 | December 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date August 16, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,520 |
Reported balance
After 2024-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-16 · Grant · Acquired 17,333 · Balance 173,520 F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 218,302 |
Reported balance
After 2024-08-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-16 · Grant · Acquired 44,782 · Balance 218,302 F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. |
| Common StockSEC Table I · non-derivative | Direct | 186,555 |
Reported balance
After 2024-08-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-08-19 · Sale · Disposed 31,747 · Balance 186,555 F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,854 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 74,739 · Balance 136,854 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
HERON THERAPEUTICS, INC. /DE/
Report date December 16, 2022 · Filed December 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,032 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Grant · Acquired 38,580 · Balance 52,032 F1: The shares were granted as restricted stock units which vest in full on December 16, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2032-12-16 | Direct | 77,160 |
Reported balance
After 2022-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-16 · Grant · Acquired 77,160 · Balance 77,160 F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on December 16, 2023.
F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2022 Filed Jun 16, 2022 14:49 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001628280-22-017341 · wf-form4_165540533246982.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| May 02, 2022 Filed May 4, 2022 00:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,483 | $18.18 | $99,691.36 |
DisclosureSEC source: 0001209191-22-026941 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,875 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.4025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026941 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Underlying: Common Stock · 15,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2022 Filed May 4, 2022 00:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-026941 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,358 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 277,331 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023737 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,331 Underlying: Common Stock · 277,331 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 69,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-023737 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,333 Underlying: Common Stock · 69,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 22:39 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 237,931 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0001209191-22-023737 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,931 Underlying: Common Stock · 237,931 shares Expires 2032-04-05 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on April 5, 2023. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 10,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013273 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,837 Underlying: Common Stock · 10,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,928 | $23.80 | $93,486.40 |
DisclosureSEC source: 0001209191-22-013273 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,733 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2022 Filed Feb 25, 2022 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-013273 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002748 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,056 Underlying: Common Stock · 9,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,718 | $23.05 | $85,699.90 |
DisclosureSEC source: 0001209191-22-002748 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,716 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 23:22 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,527 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-002748 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,434 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 1 share of the Issuer's common stock acquired by the reporting person on November 15, 2021 pursuant to an employee stock purchase program. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:31 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionRestricted Stock Units · Derivative | 18,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000409 · wf-form4_164147948805268.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock. F2 · derivative.exercise_date: The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021. F2 · derivative.expiration_date: The RSUs vest in full upon the one year anniversary of grant date on January 4, 2021. Read SEC document |
| January 04, 2022 Filed Jan 6, 2022 09:31 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 18,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-000409 · wf-form4_164147948805268.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,715 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer common stock. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 20,903 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001209191-21-071167 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,903 Underlying: Common Stock · 20,903 shares Expires 2031-12-22 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 23:55 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 10,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-071167 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,452 F1 · shares: The shares were granted as restricted stock units which vest in full on December 22, 2022. Read SEC document |
| October 18, 2021 Filed Oct 19, 2021 21:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,963 | $17.41 | $51,585.83 |
DisclosureSEC source: 0001209191-21-060957 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,906 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060957 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,938 Underlying: Common Stock · 5,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 21:30 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-060957 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,869 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 619 shares of the Issuer's common stock acquired by the reporting person on May 14, 2021 pursuant to an employee stock purchase program. Read SEC document |
| June 15, 2021 Filed Jul 7, 2021 20:25 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $3.05 | $0.00 |
DisclosureSEC source: 0001209191-21-045942 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2031-06-14 Read SEC document |
| April 30, 2021 Filed Apr 30, 2021 22:52 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 7,850 | $20.33 | $159,590.50 |
DisclosureSEC source: 0001209191-21-029356 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,312 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:52 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-029356 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,250 Underlying: Common Stock · 15,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 4/29/2020. Read SEC document |
| April 29, 2021 Filed Apr 30, 2021 22:52 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,625 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-029356 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F2 · balance_after: The amount of securities beneficially owned reported in Column 5 above has been adjusted to correct an error in the Reporting Person's prior Form 4 caused by the failure to carry over the correct number of shares from the prior report. The number of shares owned prior to the transactions reported herein was 41,537 shares. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 43,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014557 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,782 Underlying: Common Stock · 43,782 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23 2022. Read SEC document |
| February 23, 2021 Filed Feb 26, 2021 02:45 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 161,230 | $0.00 Strike: $49.74 | $0.00 |
DisclosureSEC source: 0001209191-21-014557 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,230 Underlying: Common Stock · 161,230 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on February 23, 2022. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Options (Right to Buy) · Derivative | 23,750 | $0.00 Strike: $21.28 | $0.00 |
DisclosureSEC source: 0001209191-21-008659 · doc4.xml · derivative · entry 5 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,750 Underlying: Common Stock · 23,750 shares Expires 2018-10-15 F5 · kind: On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 23,750 shares. F5 · derivative.exercise_date: On October 15, 2018, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 23,750 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Options (Right to Buy) · Derivative | 40,625 | $0.00 Strike: $35.80 | $0.00 |
DisclosureSEC source: 0001209191-21-008659 · doc4.xml · derivative · entry 4 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 40,625 shares Expires 2027-09-07 F4 · kind: On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 40,625 shares. F4 · derivative.exercise_date: On September 7, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in vesting of the option as to 40,625 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantEmployee Stock Options (Right to Buy) · Derivative | 40,625 | $0.00 Strike: $29.59 | $0.00 |
DisclosureSEC source: 0001209191-21-008659 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Common Stock · 40,625 shares Expires 2027-08-03 F3 · kind: On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 40,625 shares. F3 · derivative.exercise_date: On August 3, 2017, the reporting person was granted an option to purchase shares of common stock based upon and subject to the achievement of certain performance criteria. On February 4, 2021, the Issuer's Compensation Committee determined that certain performance criteria was achieved, resulting in the vesting of the option as to 40,625 shares. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 14,195 | $50.61 | $718,408.95 |
DisclosureSEC source: 0001209191-21-008659 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,900 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 04, 2021 Filed Feb 9, 2021 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 31,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-008659 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,059 F1 · kind: On April 29, 2019, the Issuer's Compensation Committee determined that the reporting person was granted Restricted Stock Units (RSU's) that vest upon the Issuer's satisfaction of certain performance criteria. On February 4, 2021, certain performance criteria was achieved, resulting in the vesting of the RSU's as to the number of shares reported in column 4 of row 1 above. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,527 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-002830 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,583 Underlying: Common Stock · 9,527 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,484 | $53.34 | $185,836.56 |
DisclosureSEC source: 0001209191-21-002830 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,482 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| January 06, 2021 Filed Jan 9, 2021 00:28 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,527 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-002830 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · balance_after: Includes 3,653 shares of the Issuer's common stock acquired by the reporting person on November 13, 2020 pursuant to an employee stock purchase program. Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 18:35 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantRestricted Stock Units · Derivative | 18,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-000094 · wf-form4_160988973836917.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,715 Underlying: Common Stock · 18,715 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of BLCM common stock. F2 · derivative.exercise_date: The RSUs will vest in full upon the one year anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs will vest in full upon the one year anniversary of the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $19.46 | $0.00 |
DisclosureSEC source: 0001209191-20-065009 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2030-12-21 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 21, 2020 Filed Dec 23, 2020 21:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-065009 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: The shares were granted as restricted stock units which vest in four equal quarterly installments beginning three months after the date of grant. Read SEC document |
| October 16, 2020 Filed Oct 19, 2020 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,960 | $42.56 | $125,977.60 |
DisclosureSEC source: 0001209191-20-055315 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,786 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-055315 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,876 Underlying: Common Stock · 5,937 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2020 Filed Oct 19, 2020 21:25 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,937 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-055315 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:20 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 765 | $0.00 Strike: $15.72 | $0.00 |
DisclosureSEC source: 0001209191-20-054905 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 765 Underlying: Common Stock · 765 shares Expires 2030-10-13 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in two equal monthly installments beginning one month after the date of grant. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 16:51 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | GrantStock Option (right to buy) · Derivative | 6,500 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001628280-20-009550 · wf-form4_159234068895311.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-06-14 F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable in full on the one-year anniversary of the grant date. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 88,542 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · derivative · entry 11 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 88,542 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 4,321 | $45.01 | $194,508.95 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 9 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.04, inclusive. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 84,221 | $45.65 | $3,844,596.01 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 8 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,130 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.05 to $46.04, inclusive. Read SEC document |
| May 14, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 88,542 | $19.65 | $1,739,850.30 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 7 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 111,458 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · derivative · entry 10 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,542 Underlying: Common Stock · 111,458 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 8,197 | $45.12 | $369,826.51 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 6 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,809 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.04 to $45.15, inclusive. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 63,392 | $45.71 | $2,897,857.51 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 5 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,006 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.16 to $46.15, inclusive. Read SEC document |
| May 13, 2020 Filed May 15, 2020 23:11 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 20,756 | $46.43 | $963,705.23 |
DisclosureSEC source: 0001209191-20-029858 · doc4.xml · nonDerivative · entry 4 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,398 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2019. F3 · price: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.16 to $47.15, inclusive. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.